// App-Quantinova.ai

CTNI-49 : EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM)

Researchers

Presenter

  • Fabio Iwamoto

Principal Investigators

  • Vinai Gondi

  • Nicholas Butowski

  • Gerald Falchook

  • Anja Williams

  • Katherine B Peters

  • Jeff Evans

  • Nehal Lakhani

  • Meredith McKean

  • Stefan Symeonides

  • Benjamin Ellingson

  • Jim Rotolo

  • Gina Capiaux

  • Erol Wiegert

  • Rob Michel

  • Steve Kaesshaefer

  • Alice Bexon

Medical Centers

  • Northwestern Memorial Hospital, Chicago, USA

  • Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • START Midwest, Grand Rapids, USA

  • Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

  • Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA

  • Bexon Clinical Consulting, Monclair, NJ, USA

  • UCLA Brain Tumor Imaging Laboratory, Los Angeles, CA, USA

  • Sapience Therapeutics Inc, Harrison, NY, USA

  • The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA

  • Sarah Cannon UL and UCL, London, London, United Kingdom

  • Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

  • ST101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved